<div>
  <ul>
    <li>
      <p>
        Massachusetts-based AI drug discovery company METiS Therapeutics entered into a licensing agreement with Korean precision medicine company Voronoi. The terms and financial details of the agreement have not been disclosed.
      </p>
    </li>
    <li>
      <p>
        Through the agreement, METiS will receive an exclusive license to develop and commercialize Voronoi&rsquo;s pan-RAF inhibitor program worldwide, in exchange for USD 1.7 million in upfront payment and up to USD 480.5 million upon achieving certain milestones.&nbsp;
      </p>
    </li>
    <li>
      <p>
        The pan-RAF inhibitor program will focus on treating Class II and Class III BRAF (an oncogene that promotes cancerous cell growth if mutated) mutant cancers, especially central nervous system (CNS) metastases. It will also contribute to scaling the company&rsquo;s AiTEM platform with enhanced capabilities.
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://www.businesswire.com/news/home/20220913005206/en/">
      Business Wire
    </a>
  </p>
</div>


All Updates

METiS Therapeutics enters into licensing agreement with Voronoi

METiS Therapeutics raises USD 64 million in Series A-2 financing

METiS Therapeutics emerges from stealth with USD 86 million Series A